1. Home
  2. DLPN vs LIXT Comparison

DLPN vs LIXT Comparison

Compare DLPN & LIXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DLPN
  • LIXT
  • Stock Information
  • Founded
  • DLPN 1996
  • LIXT 2005
  • Country
  • DLPN United States
  • LIXT United States
  • Employees
  • DLPN N/A
  • LIXT N/A
  • Industry
  • DLPN Other Consumer Services
  • LIXT Biotechnology: Pharmaceutical Preparations
  • Sector
  • DLPN Consumer Discretionary
  • LIXT Health Care
  • Exchange
  • DLPN Nasdaq
  • LIXT Nasdaq
  • Market Cap
  • DLPN 12.6M
  • LIXT 12.4M
  • IPO Year
  • DLPN N/A
  • LIXT N/A
  • Fundamental
  • Price
  • DLPN $1.38
  • LIXT $5.63
  • Analyst Decision
  • DLPN Strong Buy
  • LIXT
  • Analyst Count
  • DLPN 1
  • LIXT 0
  • Target Price
  • DLPN $5.00
  • LIXT N/A
  • AVG Volume (30 Days)
  • DLPN 78.9K
  • LIXT 168.6K
  • Earning Date
  • DLPN 11-13-2025
  • LIXT 11-11-2025
  • Dividend Yield
  • DLPN N/A
  • LIXT N/A
  • EPS Growth
  • DLPN N/A
  • LIXT N/A
  • EPS
  • DLPN N/A
  • LIXT N/A
  • Revenue
  • DLPN $51,257,243.00
  • LIXT N/A
  • Revenue This Year
  • DLPN $9.05
  • LIXT N/A
  • Revenue Next Year
  • DLPN $15.42
  • LIXT N/A
  • P/E Ratio
  • DLPN N/A
  • LIXT N/A
  • Revenue Growth
  • DLPN 4.84
  • LIXT N/A
  • 52 Week Low
  • DLPN $0.75
  • LIXT $0.64
  • 52 Week High
  • DLPN $1.78
  • LIXT $6.26
  • Technical
  • Relative Strength Index (RSI)
  • DLPN 67.15
  • LIXT 65.38
  • Support Level
  • DLPN $1.14
  • LIXT $4.28
  • Resistance Level
  • DLPN $1.21
  • LIXT $6.26
  • Average True Range (ATR)
  • DLPN 0.06
  • LIXT 0.62
  • MACD
  • DLPN 0.02
  • LIXT 0.16
  • Stochastic Oscillator
  • DLPN 100.00
  • LIXT 78.28

About DLPN Dolphin Entertainment Inc.

Dolphin Entertainment Inc is an independent entertainment marketing and production company. It provides strategic marketing and publicity services to many of the top brands, both individual and corporate, in the motion picture, television, music, gaming, culinary, hospitality, and lifestyle industries. It operates in two reportable segments: Entertainment publicity and marketing and Content production. It generates the majority of its revenue from the Entertainment publicity and marketing segment which provides clients with diversified marketing services, including public relations, entertainment and hospitality content marketing, strategic marketing consulting, and content production of marketing materials.

About LIXT Lixte Biotechnology Holdings Inc.

Lixte Biotechnology Holdings Inc is a biopharmaceutical company dedicated to improving patients' lives by developing a drug class called Protein Phosphatase 2A inhibitors. Its product pipeline is focused on inhibitors of protein phosphatase 2A, used in combination with cytotoxic agents and/or x-rays, immune checkpoint blockers, and other cancer therapies. The Company believes that inhibitors of protein phosphatases have therapeutic potential for a broad range of cancers. It focuses on the clinical development of a specific protein phosphatase inhibitor, referred to as LB-100, which has been shown to have clinical anti-cancer activity at doses that produce little or no toxicity.

Share on Social Networks: